Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Nanodomain Engineering using a X-omics blueprint of the NK cell Surface

Objetivo

Natural killer (NK) cells hold enormous promise for cancer therapy, which is explored in nearly 400 clinical trials. Yet, on average only about 40% of patients respond to treatment and it remains difficult to predict why. This challenge stems from a fundamental unknown: how do NK cells decide whether to kill a tumor cell? Traditional models assume this decision is governed by a simple balance of activating and inhibitory receptors, but mounting evidence suggests a more intricate mechanism: the nanoscale spatial organization of these receptors appears to encode specific instructions that determine NK cell behavior. I project that a proximity labeling platform I recently developed represents a key foundation to decipher this code.

In my ERC project called NEXUS I will:
1) Apply a new cutting-edge nanoscale proteomics approach to systematically chart the nanoscale distribution of key NK receptors and their coregulators on the membrane of cultured and primary human NK cells across various activating and repressive conditions.
2) Develop a new spatial interaction proteomics approach to define which receptor-ligand interactions guide NK recognition of tumor targets.
3) Engineer NK cells with optogenetically tunable receptor clustering to causally test how specific receptor organizations govern NK cell activation, immune synapse formation, and target killing.

Together, NEXUS will redefine our understanding of NK cell biology and establish a generalizable framework for how immune cells interpret complex signals through spatial organization. This could open an entirely new dimension of immune regulation and reshape the way we think about immune decision-making, and move immunotherapy design beyond trial-and-error towards new rational, spatially informed NK-cell therapies with transformative potential for cancer treatment.

Ámbito científico (EuroSciVoc)

Este proyecto aún no se ha clasificado con EuroSciVoc.
Sugiera los ámbitos científicos que considere más relevantes y ayúdenos a mejorar nuestro servicio de clasificación.

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC - HORIZON ERC Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2026-STG

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Aportación neta de la UEn
€ 1 500 000,00
Dirección
GEERT GROOTEPLEIN 10 ZUID
6525 GA Nijmegen
Países Bajos
Región
Oost-Nederland Gelderland Arnhem/Nijmegen
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 1 500 000,00

Beneficiarios (1)